

## **PUBLICATIONS HEPATITES 2009**

1. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, Pohl RT, Pawlotsky JM. Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. *Gastroenterology* 2009.
2. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. *Liver Int* 2009.
3. Bani-Sadr F. [Treatment of chronic hepatitis C in HIV-infected patients]. *Gastroenterologie clinique et biologique* 2009;33 Suppl 2:S97-S103.
4. Bani-Sadr F. [ANRS HC 02 RIBAVIC: summary and recommandations]. *Gastroenterologie clinique et biologique* 2009;33 Suppl 2:S104-105.
5. Bani-Sadr F, Barange K, Daoud F, Jacomet C, Bicart-See A, Rosenthal E, Cacoub P, Pol S, Perronne C, Carrat F. Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosis. *HIV medicine* 2009;10:417-421.
6. Bani-Sadr F, Bedossa P, Rosenthal E, Merrien D, Perre P, Lascoux-Combe C, Cacoub P, Perronne C, Pol S. Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients? *Journal of acquired immune deficiency syndromes (1999)* 2009;50:234-236.
7. Bani-Sadr F, Lapidus N, Rosenthal E, Gerard L, Foltzer A, Perronne C, Cacoub P, Pol S, Carrat F. Gamma glutamyl transferase elevation in HIV/Hepatitis C virus-coinfected patients during interferon-ribavirin combination therapy. *Journal of acquired immune deficiency syndromes (1999)* 2009;50:429-430.
8. Baril M, Racine ME, Penin F, Lamarre D. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. *Journal of virology* 2009;83:1299-1311.
9. Bartosch B, Cosset FL. Studying HCV cell entry with HCV pseudoparticles (HCVpp). *Methods in molecular biology (Clifton, NJ)* 2009;510:279-293.
10. Bartosch B, Thimme R, Blum HE, Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. *Journal of hepatology* 2009;51:810-820.
11. Bedossa P, Carrat F. Liver fibrosis: screening is not staging. *Journal of hepatology* 2009;50:1268-1269.
12. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. *Journal of hepatology* 2009;50:1-3.

13. Benedicto I, Molina-Jimenez F, Bartosch B, Cosset FL, Lavillette D, Prieto J, Moreno-Otero R, Valenzuela-Fernandez A, Aldabe R, Lopez-Cabrera M, Majano PL. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. *Journal of virology* 2009;83:8012-8020.
14. Bonorino P, Ramzan M, Camous X, Dufeu-Duchesne T, Thelu MA, Sturm N, Dariz A, Guillermet C, Pernollet M, Zarski JP, Marche PN, Leroy V, Jouvin-Marche E. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. *Journal of hepatology* 2009;51:458-467.
15. Borgniet O, Parvaz P, Bouix C, Chevallier P, Trepo C, Andre P, Zoulim F. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. *Journal of medical virology* 2009;81:1336-1342.
16. Bottero J, Lacombe K, Guechot J, Serfaty L, Miaillhes P, Bonnard P, Wendum D, Molina JM, Lascoux-Combe C, Girard PM. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. *Journal of hepatology* 2009;50:1074-1083.
17. Boursier J, Bacq Y, Halfon P, Leroy V, de Ledinghen V, de Muret A, Bourliere M, Sturm N, Foucher J, Oberti F, Rousselet MC, Cales P. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. *European journal of gastroenterology & hepatology* 2009;21:28-38.
18. Boyd A, Lacombe K, Miaillhes P, Gozlan J, Bonnard P, Molina JM, Lascoux-Combe C, Serfaty L, Gault E, Desvarieux M, Girard PM. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. *Journal of viral hepatitis*;17:65-76.
19. Brohm C, Steinmann E, Friesland M, Lorenz IC, Patel A, Penin F, Bartenschlager R, Pietschmann T. Characterization of determinants important for hepatitis C virus p7 function in morphogenesis by using trans-complementation. *Journal of virology* 2009;83:11682-11693.
20. Buckwalter MR, Albert ML. Orchestration of the immune response by dendritic cells. *Curr Biol* 2009;19:R355-361.
21. Budkowska A. Mechanism of cell infection with hepatitis C virus (HCV)--a new paradigm in virus-cell interaction. *Polish journal of microbiology / Polskie Towarzystwo Mikrobiologow = The Polish Society of Microbiologists* 2009;58:93-98.
22. Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. *The Journal of general virology* 2009;90:1055-1070.
23. Cacoub P, Carrat F, Bedossa P, Lambert J, Penaranda G, Pol S, Halfon P. Insulin resistance impairs sustained virological response rate to pegylated interferon plus

ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. *Antiviral therapy* 2009;14:839-845.

24. Carpentier A, Conti F, Carriere M, Aoudjehane L, Miroux C, Morales O, Calmus Y, Groux H, Auriault C, Pancre V, Delhem N, Podevin P. Analysis of gene transcription in sera during chronic hepatitis C infection. *Journal of medical virology* 2009;81:473-480.

25. Carpentier A, Conti F, Stenard F, Aoudjehane L, Miroux C, Podevin P, Morales O, Chouzenoux S, Scatton O, Groux H, Auriault C, Calmus Y, Pancre V, Delhem N. Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. *Am J Transplant* 2009;9:2102-2112.

26. Chemin I, Guillaud O, Queyron PC, Trepo C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. *Journal of hepatology* 2009;51:824-825.

27. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. *PLoS one* 2009;4:e8209.

28. Chevaliez S, Bouvier-Alias M, Castera L, Pawlotsky JM. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. *Hepatology (Baltimore, Md)* 2009;49:1397-1398.

29. Chevaliez S, Bouvier-Alias M, Pawlotsky JM. Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. *Journal of clinical microbiology* 2009;47:1726-1732.

30. Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, Zoulim F, Op de Beeck A, Neyts J. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. *Hepatology (Baltimore, Md)* 2009;50:6-16.

31. Delarocque-Astagneau E, Meffre C, Dubois F, Pioche C, Le Strat Y, Roudot-Thoraval F, Hillon P, Silvain C, Dhumeaux D, Desenclos JC. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. *Journal of viral hepatitis* 2009.

32. Desjardins D, Huret C, Dalba C, Kreppel F, Kochanek S, Cosset FL, Tangy F, Klatzmann D, Bellier B. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. *The journal of gene medicine* 2009;11:313-325.

33. Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yazdanpanah Y. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection. *Gut* 2009;58:105-110.

34. Deuffic-Burban S, Babany G, Lonjon-Domanec I, Deltenre P, Canva-Delcambre V, Dharancy S, Louvet A, Roudot-Thoraval F, Mathurin P. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. *Hepatology (Baltimore, Md)* 2009;50:1351-1359.
35. Deuffic-Burban S, Mathurin P, Valleron AJ. Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. *Statistical methods in medical research* 2009;18:233-252.
36. Dreux M, Cosset FL. Detection of neutralizing antibodies with HCV pseudoparticles (HCVpp). *Methods in molecular biology (Clifton, NJ)* 2009;510:427-438.
37. Dreux M, Dao Thi VL, Fresquet J, Guerin M, Julia Z, Verney G, Durantel D, Zoulim F, Lavillette D, Cosset FL, Bartosch B. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. *PLoS pathogens* 2009;5:e1000310.
38. Dubois A, Francois C, Descamps V, Fournier C, Wychowski C, Dubuisson J, Castelain S, Duverlie G. Enhanced anti-HCV activity of interferon alpha 17 subtype. *Virology journal* 2009;6:70.
39. Durantel D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. *Curr Opin Investig Drugs* 2009;10:860-870.
40. Durantel D, Zoulim F. Innate response to hepatitis B virus infection: observations challenging the concept of a stealth virus. *Hepatology (Baltimore, Md)* 2009;50:1692-1695.
41. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekecewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. *Journal of medical virology* 2009;81:1576-1583.
42. Eyre NS, Baumert TF, Beard MR. Closing the gap: the tight junction protein occludin and hepatitis C virus entry. *Hepatology (Baltimore, Md)* 2009;49:1770-1772.
43. Fremin C, Bessard A, Ezan F, Gailhouste L, Regeard M, Le Seyec J, Gilot D, Pages G, Pouyssegur J, Langouet S, Baffet G. Multiple division cycles and long-term survival of hepatocytes are distinctly regulated by extracellular signal-regulated kinases ERK1 and ERK2. *Hepatology (Baltimore, Md)* 2009;49:930-939.
44. Gamble C, Trotard M, Le Seyec J, Abreu-Guerniou V, Gernigon N, Berree F, Carboni B, Felden B, Gillet R. Antiviral effect of ribonuclease conjugated oligodeoxynucleotides targeting the IRES RNA of the hepatitis C virus. *Bioorganic & medicinal chemistry letters* 2009;19:3581-3585.

45. Gondeau C, Pichard-Garcia L, Maurel P. Cellular models for the screening and development of anti-hepatitis C virus agents. *Pharmacology & therapeutics* 2009;124:1-22.
46. Gondois-Rey F, Dental C, Halfon P, Baumert TF, Olive D, Hirsch I. Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. *PloS one* 2009;4:e4319.
47. Gouttenoire J, Castet V, Montserret R, Arora N, Raussens V, Ruyschaert JM, Diesis E, Blum HE, Penin F, Moradpour D. Identification of a novel determinant for membrane association in hepatitis C virus nonstructural protein 4B. *Journal of virology* 2009;83:6257-6268.
48. Gouttenoire J, Montserret R, Kennel A, Penin F, Moradpour D. An amphipathic alpha-helix at the C terminus of hepatitis C virus nonstructural protein 4B mediates membrane association. *Journal of virology* 2009;83:11378-11384.
49. Guechot J, Lasnier E, Sturm N, Paris A, Zarski JP. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. *Clinica chimica acta; international journal of clinical chemistry*;411:86-91.
50. Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. *Current opinion in molecular therapeutics* 2009;11:456-462.
51. Haid S, Pietschmann T, Pecheur EI. Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. *The Journal of biological chemistry* 2009;284:17657-17667.
52. Halfon P, Carrat F, Bedossa P, Lambert J, Penaranda G, Perronne C, Pol S, Cacoub P. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02. *Antiviral therapy* 2009;14:211-219.
53. Halfon P, Martinot-Peignoux M, Cacoub P. The myth of occult hepatitis C infection. *Hepatology (Baltimore, Md)* 2009;50:1675.
54. Halfon P, Penaranda G, Cacoub P. [ANRS-fibrovic and homavic: role of non invasive markers of liver fibrosis and insulin-resistance during antiviral treatment in HIV-HCV co-infected patients from ANRS HC 02 RIVABIC trial]. *Gastroenterologie clinique et biologique* 2009;33 Suppl 2:S113-117.
55. Halfon P, Penaranda G, Cacoub P. [ANRS-fibrovic and homavic: role of non invasive markers of liver fibrosis and insulin resistance during antiviral treatment in HIV-HCV co-

infected patients from ANRS HC 02 RIVABIC trial]. *Gastroenterologie clinique et biologique* 2009; 33 Suppl 2:S113-117.

56. Halfon P, Penaranda G, Carrat F, Bedossa P, Bourliere M, Ouzan D, Renou C, Tran A, Rosenthal E, Wartelle C, Delasalle P, Cacoub P. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. *Alimentary pharmacology & therapeutics* 2009; 30: 61-70.

57. Hanouille X, Badillo A, Wieruszeski JM, Verdegem D, Landrieu I, Bartenschlager R, Penin F, Lippens G. Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. *The Journal of biological chemistry* 2009; 284: 13589-13601.

58. Hanouille X, Verdegem D, Badillo A, Wieruszeski JM, Penin F, Lippens G. Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. *Biochemical and biophysical research communications* 2009; 381: 634-638.

59. Hantz O, Parent R, Durantel D, Gripon P, Guguen-Guillouzo C, Zoulim F. Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. *The Journal of general virology* 2009; 90: 127-135.

60. Haurie V, Menard L, Nicou A, Touriol C, Metzler P, Fernandez J, Taras D, Lestienne P, Balabaud C, Bioulac-Sage P, Prats H, Zucman-Rossi J, Rosenbaum J. Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism. *Hepatology (Baltimore, Md)* 2009; 50: 1871-1883.

61. Icard V, Diaz O, Scholtes C, Perrin-Cocon L, Ramiere C, Bartenschlager R, Penin F, Lotteau V, Andre P. Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. *PLoS one* 2009; 4: e4233.

62. Izzedine H, Sene D, Cacoub P, Jansen H, Camous L, Brocheriou I, Bourry E, Deray G. Kidney diseases in HIV/HCV-co-infected patients. *AIDS (London, England)* 2009; 23: 1219-1226.

63. Jauffret-Roustide M, Le Strat Y, Couturier E, Thierry D, Rondy M, Quaglia M, Razafandratsima N, Emmanuelli J, Guibert G, Barin F, Desenclos JC. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. *BMC infectious diseases* 2009; 9: 113.

64. Kota S, Coito C, Mousseau G, Lavergne JP, Strosberg AD. Peptide inhibitors of hepatitis C virus core oligomerization and virus production. *The Journal of general virology* 2009; 90: 1319-1328.

65. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C, Baumert TF. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is

mediated by neutralization of E2-CD81-Claudin-1 associations. *Hepatology (Baltimore, Md)* 2009.

66. Ladeiro Y, Zucman-Rossi J. [miRNAs in cancer: the case of liver tumors]. *Med Sci (Paris)* 2009;25:467-472.

67. Le Duff Y, Blanchet M, Sureau C. The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. *Journal of virology* 2009;83:12443-12451.

68. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, Bouviers-Alias M, Trimoulet P, Chaix ML, Hezode C, Foucher J, Fontaine H, Roque-Afonso AM, Gassin M, Schvoerer E, Gaudy C, Roche B, Doffoel M, D'Alteroche L, Vallet S, Baazia Y, Pozzetto B, Thibault V, Nousbaum JB, Roulot D, Coppere H, Poinard T, Payan C, Izopet J. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. *Journal of medical virology* 2009;81:2029-2035.

69. Legrand-Abravanel F, Henquell C, Le Guillou-Guillemette H, Balan V, Mirand A, Dubois M, Lunel-Fabiani F, Payan C, Izopet J. Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naïve patients infected with genotypes 1-5. *Antiviral therapy* 2009;14:723-730.

70. Lepere-Douard C, Trotard M, Le Seyec J, Gripon P. The first transmembrane domain of the hepatitis B virus large envelope protein is crucial for infectivity. *Journal of virology* 2009;83:11819-11829.

71. Lerat H, Kammoun HL, Hainault I, Merour E, Higgs MR, Callens C, Lemon SM, Fougelle F, Pawlotsky JM. Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. *The Journal of biological chemistry* 2009;284:33466-33474.

72. Loulergue P, Pol S, Mallet V, Sogni P, Launay O. Why actively promote vaccination in patients with cirrhosis? *J Clin Virol* 2009;46:206-209.

73. Loustaud-Ratti V, Rousseau A, Marquet P, Denis F, Alain S. Ribavirin in chronic hepatitis C: past and future. *Expert review of anti-infective therapy* 2009;7:249-253.

74. Lupo J, Larrat S, Hilleret MN, Germi R, Boyer V, Nicod S, Bargues G, Leroy V, Seigneurin JM, Zarski JP, Morand P. Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. *Journal of virological methods* 2009;156:52-58.

75. Mallet VO, Vallet-Pichard A, Pol S. Human immunodeficiency virus-associated obliterative portopathy underlies unexplained aminotransferase elevations under antiretrovirals. *Hepatology (Baltimore, Md)* 2009;50:660.

76. Mansuy JM, Huynh A, Abravanel F, Recher C, Peron JM, Izopet J. Molecular evidence of patient-to-patient transmission of hepatitis E virus in a hematology ward. *Clin Infect Dis* 2009; 48: 373-374.
77. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. *Gastroenterology* 2009; 136: 2169-2179 e2161-2164.
78. Martinot-Peignoux M, Khiri H, Leclere L, Maylin S, Marcellin P, Halfon P. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C. *J Clin Virol* 2009; 46: 216-221.
79. Marvie P, Lisbonne M, L'Helgoualc'h A, Rauch M, Turlin B, Preisser L, Bourd-Boittin K, Theret N, Gascan H, Piquet-Pellorce C, Samson M. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. *Journal of cellular and molecular medicine* 2009.
80. Matignon M, Cacoub P, Colombat M, Saadoun D, Brocheriou I, Mougnot B, Roudot-Thoraval F, Vanhille P, Moranne O, Hachulla E, Hatron PY, Fermand JP, Fakhouri F, Ronco P, Plaisier E, Grimbert P. Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. *Medicine* 2009; 88: 341-348.
81. Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau JM, Cosset FL, Chayama K, Vaillant A, Liang TJ. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. *Gastroenterology* 2009; 137: 673-681.
82. Mee CJ, Farquhar MJ, Harris HJ, Hu K, Ramma W, Ahmed A, Maurel P, Bicknell R, Balfe P, McKeating JA. Hepatitis C Virus Infection Reduces Hepatocellular Polarity in a Vascular Endothelial Growth Factor-Dependent Manner. *Gastroenterology* 2009.
83. Mello IM, Thumann C, Schvoerer E, Soulier E, Pinho JR, Silvestre DA, Queiroz AT, Wolf P, Baumert TF, Keller FS, Pereira CA. Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation. *Journal of viral hepatitis* 2009; 16: 732-737.
84. Meynard JL, Lacombe K, Poirier JM, Legrand J, Morand-Joubert L, Girard PM. Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. *The Journal of antimicrobial chemotherapy* 2009; 63: 579-584.
85. Mialhes P, Pradat P, Trepo C. Influence of aminotransferase values on liver stiffness measurement: the case of HIV-infected patients with acute viral hepatitis B or C. *HIV medicine* 2009; 10: 62-63.

86. Michel L, Villes V, Dabis F, Spire B, Winnock M, Loko MA, Poizot-Martin I, Valantin MA, Bonnard P, Salmon-Ceron D, Carrieri MP. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepaviv, France, 2006-2008. *Journal of viral hepatitis* 2009.
87. Moenne-Loccoz R, Razafinjatovo C, Habersetzer F, Ananna A, Doffoel M, Wolf P, Gut JP, Baumert T, Stoll-Keller F, Schvoerer E. [Tropism of hepatitis C virus for leukocytes - Importance of the analysis of viral E1 and E2 envelope glycoprotein genes by sequencing.]. *Pathologie-biologie* 2009.
88. Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis. *Journal of hepatology* 2009.
89. Morice Y, Ratinier M, Miladi A, Chevaliez S, Germanidis G, Wedemeyer H, Laperche S, Lavergne JP, Pawlotsky JM. Seroconversion to hepatitis C virus alternate reading frame protein during acute infection. *Hepatology (Baltimore, Md)* 2009;49:1449-1459.
90. Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. *Journal of hepatology* 2009;50:1084-1092.
91. Moucari R, Martinot-Peignoux M, Mackiewicz V, Boyer N, Ripault MP, Castelnau C, Leclere L, Dauvergne A, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. *Antiviral therapy* 2009;14:1183-1188.
92. Moucari R, Ripault MP, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C, Boyer N, Maylin S, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. *Gut* 2009;58:1662-1669.
93. Nahon P, Kettaneh A, Lemoine M, Seror O, Barget N, Trinchet JC, Beaugrand M, Ganne-Carrie N. Liver stiffness measurement in patients with cirrhosis and hepatocellular carcinoma: a case-control study. *European journal of gastroenterology & hepatology* 2009;21:214-219.
94. Narayan R, Gangadharan B, Hantz O, Antrobus R, Garcia A, Dwek RA, Zitzmann N. Proteomic analysis of HepaRG cells: a novel cell line that supports hepatitis B virus infection. *Journal of proteome research* 2009;8:118-122.
95. Navratil V, de Chasse B, Meyniel L, Delmotte S, Gautier C, Andre P, Lotteau V, Rouboudin-Combe C. VirHostNet: a knowledge base for the management and the analysis of proteome-wide virus-host interaction networks. *Nucleic acids research* 2009;37:D661-668.

96. Ndongo N, Rechoum Y, De Sequeira S, Zoulim F, Trepo C, Drouet E, Petit MA. Inhibition of the binding of HCV serum particles to human hepatocytes by E1E2-specific D32.10 monoclonal antibody. *Journal of medical virology* 2009;81:1726-1733.
97. N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E, Vicaut E, Trinchet JC, Sellier N, Beaugrand M, Seror O. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. *Hepatology (Baltimore, Md)* 2009;50:1475-1483.
98. Pallier C, Rodriguez C, Brillet R, Nordmann P, Hezode C, Pawlotsky JM. Complex dynamics of hepatitis B virus resistance to adefovir. *Hepatology (Baltimore, Md)* 2009;49:50-59.
99. Patient R, Hourieux C, Roingeard P. Morphogenesis of hepatitis B virus and its subviral envelope particles. *Cellular microbiology* 2009;11:1561-1570.
100. Patient R, Hourieux C, Vaudin P, Pages JC, Roingeard P. Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. *New biotechnology* 2009;25:226-234.
101. Paz S, Vilasco M, Arguello M, Sun Q, Lacoste J, Nguyen TL, Zhao T, Shestakova EA, Zaari S, Bibeau-Poirier A, Servant MJ, Lin R, Meurs EF, Hiscott J. Ubiquitin-regulated recruitment of IkappaB kinase epsilon to the MAVS interferon signaling adapter. *Molecular and cellular biology* 2009;29:3401-3412.
102. Pellet J, Tafforeau L, Lucas-Hourani M, Navratil V, Meyniel L, Achaz G, Guironnet-Paquet A, Aublin-Gex A, Caignard G, Cassonnet P, Chaboud A, Chantier T, Deloire A, Demeret C, Le Breton M, Neveu G, Jacotot L, Vaglio P, Delmotte S, Gautier C, Combet C, Deleage G, Favre M, Tangy F, Jacob Y, Andre P, Lotteau V, Rabourdin-Combe C, Vidalain PO. ViralORFeome: an integrated database to generate a versatile collection of viral ORFs. *Nucleic acids research*;38:D371-378.
103. Pelletier L, Rebouissou S, Paris A, Rathahao-Paris E, Perdu E, Bioulac-Sage P, Imbeaud S, Zucman-Rossi J. Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. *Hepatology (Baltimore, Md)* 2009;51:557-566.
104. Perard J, Rasia R, Medenbach J, Ayala I, Boisbouvier J, Drouet E, Baudin F. Human initiation factor eIF3 subunit b interacts with HCV IRES RNA through its N-terminal RNA recognition motif. *FEBS letters* 2009;583:70-74.
105. Perrault M, Pecheur EI. The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership. *The Biochemical journal* 2009;423:303-314.
106. Pfeffer S, Baumert TF. Unravelling the importance of microRNAs during hepatitis C virus infection in the human liver. *Journal of hepatology* 2009;51:606-609.

107. Pol S. [ANRS HC 02 RIBAVIC: impact of steatosis in HIV-HCV co-infection]. *Gastroenterologie clinique et biologique* 2009;33 Suppl 2:S110-112.
108. Pol S. [ANRS HC 02 RIBAVIC: histo-pathological impact]. *Gastroenterologie clinique et biologique* 2009;33 Suppl 2:S106-109.
109. Popescu CI, Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. *Biology of the cell / under the auspices of the European Cell Biology Organization*;102:63-74.
110. Ratinier M, Boulant S, Crussard S, McLauchlan J, Lavergne JP. Subcellular localizations of the hepatitis C virus alternate reading frame proteins. *Virus research* 2009;139:106-110.
111. Rocha-Perugini V, Lavie M, Delgrange D, Canton J, Pillez A, Potel J, Lecoœur C, Rubinstein E, Dubuisson J, Wychowski C, Cocquerel L. The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry. *BMC microbiology* 2009;9:111.
112. Roohvand F, Maillard P, Lavergne JP, Boulant S, Walic M, Andreo U, Goueslain L, Helle F, Mallet A, McLauchlan J, Budkowska A. Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein. *The Journal of biological chemistry* 2009;284:13778-13791.
113. Rosenthal E, Salmon-Ceron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, Karmochkine M, May T, Francois M, Burty C, Jouglu E, Costagliola D, Morlat P, Chene G, Cacoub P. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). *HIV medicine* 2009;10:282-289.
114. Saint N, Montserret R, Chipot C, Penin F. Structural and functional analysis of the HCV p7 protein. *Methods in molecular biology (Clifton, NJ)* 2009;510:125-143.
115. Salisse J, Sureau C. A function essential to viral entry underlies the hepatitis B virus "a" determinant. *Journal of virology* 2009;83:9321-9328.
116. Samri A, Roque-Afonso AM, Beran O, Tateo M, Teicher E, Feray C, Sebah M, Guettier C, Dussaix E, Vittecoq D, Samuel D, Autran B, Duclos-Vallee JC. Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV-HCV coinfecting patients (ANRS-HC08 "THEVIC" trial). *Journal of hepatology* 2009;51:1000-1009.
117. Santantonio T, Fasano M, Durantel S, Barraud L, Heichen M, Guastadisegni A, Pastore G, Zoulim F. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. *Antiviral therapy* 2009;14:557-565.

118. Schnuriger A, Dominguez S, Guiguet M, Harfouch S, Samri A, Ouazene Z, Slama L, Simon A, Valantin MA, Thibault V, Autran B. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. *AIDS (London, England)* 2009;23:2079-2089.
119. Schregel V, Jacobi S, Penin F, Tautz N. Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3. *Proceedings of the National Academy of Sciences of the United States of America* 2009;106:5342-5347.
120. Schuster C, Baumert TF. EWI-2wint--a host cell factor inhibiting hepatitis C virus entry. *Journal of hepatology* 2009;50:222-224.
121. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Guido M, Bourliere M, Noventa F, Alberti A. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. *Hepatology (Baltimore, Md)* 2009;49:1821-1827.
122. Simister P, Schmitt M, Geitmann M, Wicht O, Danielson UH, Klein R, Bressanelli S, Lohmann V. Structural and functional analysis of hepatitis C virus strain JFH1 polymerase. *Journal of virology* 2009;83:11926-11939.
123. Simonin Y, Disson O, Lerat H, Antoine E, Biname F, Rosenberg AR, Desagher S, Lassus P, Bioulac-Sage P, Hibner U. Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway. *Hepatology (Baltimore, Md)* 2009;50:1370-1379.
124. Slama L, Le Camus C, Serfaty L, Pialoux G, Capeau J, Gharakhanian S. Metabolic disorders and chronic viral disease: the case of HIV and HCV. *Diabetes & metabolism* 2009;35:1-11.
125. Szecsi J, Gabriel G, Edfeldt G, Michelet M, Klenk HD, Cosset FL. DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus. *The Journal of infectious diseases* 2009;200:181-190.
126. Tateo M, Roque-Afonso AM, Antonini TM, Medja F, Lombes A, Jardel C, Teicher E, Sebah M, Roche B, Castaing D, Samuel D, Duclos-Vallee JC. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfecting patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. *AIDS (London, England)* 2009;23:1069-1076.
127. Tews BA, Cocquerel L. [Occludin, an additional key for hepatitis C virus entry]. *Med Sci (Paris)* 2009;25:549-551.

128. Thibault V, Laperche S, Akhavan S, Servant-Delmas A, Belkhiri D, Roque-Afonso AM. Impact of hepatitis B virus genotypes and surface antigen variants on the performance of HBV real time PCR quantification. *Journal of virological methods* 2009; 159:265-270.

129. Tian ZF, Shen H, Fu XH, Chen YC, Blum HE, Baumert TF, Zhao XP. Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81. *World J Gastroenterol* 2009; 15:240-244.

130. Trabut JB, Mallet V, Pol S. Aspartate aminotransferase to platelet ratio index (APRI) score is inappropriate for assessment of liver fibrosis in HIV-infected patients with hazardous drinking. *HIV medicine* 2009; 10:524; author reply 524-525.

131. Trepo C, Pradat P. Hepatitis C: CIFN for re-treatment of PEG-IFN plus RBV nonresponders? *Nature reviews* 2009; 6:570-571.

132. Trotard M, Lepere-Douard C, Regeard M, Piquet-Pellorce C, Lavillette D, Cosset FL, Gripon P, Le Seyec J. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. *Faseb J* 2009; 23:3780-3789.

133. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, Vogel M, Baumgarten A, Chaix ML, Fisher M, Gotz H, Matthews GV, Neifer S, White P, Rawlinson W, Pol S, Rockstroh J, Coutinho R, Dore GJ, Dusheiko GM, Danta M. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. *Gastroenterology* 2009; 136:1609-1617.

134. Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, Callewaert N. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. *Mol Cell Proteomics* 2009; 8:986-994.

135. Vieyres G, Angus AG, Haberstroh A, Baumert TF, Dubuisson J, Patel AH. Rapid synchronization of hepatitis C virus infection by magnetic adsorption. *Journal of virological methods* 2009; 157:69-79.

136. Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Deny P, Zoulim F. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. *Gastroenterology* 2009; 136:168-176 e162.

137. Vincent IE, Lucifora J, Durantel D, Hantz O, Chemin I, Zoulim F, Trepo C. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. *Antiviral therapy* 2009; 14: 131-135.

138. Vitour D, Dabo S, Ahmadi Pour M, Vilasco M, Vidalain PO, Jacob Y, Mezel-Lemoine M, Paz S, Arguello M, Lin R, Tangy F, Hiscott J, Meurs EF. Polo-like kinase 1 (PLK1) regulates interferon (IFN) induction by MAVS. *The Journal of biological chemistry* 2009; 284:21797-21809.

139. Warter L, Cohen L, Benureau Y, Chavez D, Yang Y, Bodola F, Lemon SM, Traboni C, Lanford RE, Martin A. A cooperative interaction between nontranslated RNA sequences and NS5A protein promotes in vivo fitness of a chimeric hepatitis C/GB virus B. *PLoS one* 2009;4:e4419.
140. Weatherford T, Chavez D, Brasky KM, Lemon SM, Martin A, Lanford RE. Lack of adaptation of chimeric GB virus B/hepatitis C virus in the marmoset model: possible effects of bottleneck. *Journal of virology* 2009;83:8062-8075.
141. Welbourn S, Jirasko V, Breton V, Reiss S, Penin F, Bartenschlager R, Pause A. Investigation of a role for lysine residues in non-structural proteins 2 and 2/3 of the hepatitis C virus for their degradation and virus assembly. *The Journal of general virology* 2009;90:1071-1080.
142. Wendum D, Lacombe K, Chevallier M, Callard P, Valet F, Miaillhes P, Bonnard P, Molina JM, Lascoux-Combe C, Flejou JF, Girard PM. Histological scoring of fibrosis and activity in HIV-chronic hepatitis B related liver disease: performance of the METAVIR score assessed on virtual slides. *Journal of clinical pathology* 2009;62:361-363.
143. Weseslindtner L, Neumann-Haefelin C, Viazov S, Haberstroh A, Kletzmayer J, Aberle JH, Timm J, Ross SR, Klauser-Braun R, Baumert TF, Roggendorf M, Thimme R, Holzmann H. Acute infection with a single hepatitis C virus strain in dialysis patients: Analysis of adaptive immune response and viral variability. *Journal of hepatology* 2009;50:693-704.
144. Zeisel MB, Baumert TF. HCV entry and neutralizing antibodies: lessons from viral variants. *Future microbiology* 2009;4:511-517.
145. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. *Gastroenterology* 2009;137:1593-1608 e1591-1592.
146. Zucman-Rossi J, Clement B, Buendia MA, Lerat H, Beers BV, Bedossa P, Taieb J, Rosenbaum J. [Fundamental and translational research on hepatocellular carcinoma in 2008: forces and priorities]. *Bulletin du cancer* 2009;96:45-50.
147. Tews BA, Dubuisson J. Occludin, the final essential factor for HCV entry? *Future Virology*, 2009, 4, 329-333.